GeNeuro, a Geneva-based biopharmaceutical company focusing on treatments for neurodegenerative and autoimmune diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and severe neuropsychiatric consequences of COVID-19 (post-COVID), has successfully completed a €5 million capital increase.
![Successful € 5 Million Capital Increase for GeNeuro](https://republic-of-innovation.ch/wordpress/wp-content/uploads/2024/02/BioAlps-Website-768x477-26-630x391.png)